Multiple myeloma in association with sarcoidosis: a case report and review of the literature. (Case Reports).
An association between sarcoidosis and malignant neoplasms has been suggested. (3,4) In particular, patients with sarcoidosis may also develop a lymphoproliferative disorder. Usually, the lymphoproliferative disorder follows the onset of sarcoidosis by more than one year. Hodgkin disease is the most common lymphoid neoplasm; however, many different types of non-Hodgkin lymphomas and lymphoid leukemias also have been reported in patients with sarcoidosis. Brincker (5) suggested the term sarcoidosis-lymphoma syndrome for this association in 1986.
Rarely, cases of sarcoidosis associated with multiple myeloma also have been reported, mostly in the clinical literature. (5-10) In this report, we describe a woman who developed multiple myeloma 4 years after the diagnosis of sarcoidosis, and we review the relevant literature.
REPORT OF A CASE
A 49-year-old black woman was admitted to the hospital in June 1998 for severe low back pain and weakness of her lower extremities.
The patient's past medical history was significant for severe disabling sarcoidosis, first diagnosed in January 1994, involving the lungs, eyes, lymph nodes, and bone marrow. Complete blood cell count revealed the following values: white blood cell count, 3.5 x [10.sup.9]/L (reference range, 3.2-9.8 x [10.sup.9]/L); hemoglobin, 83 g/L (reference range, 120-155 g/L); hematocrit, 0.26 (reference range, 0.35-0.45); and platelet count, 224 x [10.sup.9]/L (reference range, 150-450 x [10.sup.9]/L). The patient's total serum protein level was 84 g/L (reference range, 60-80 g/L). Serum protein electrophoresis revealed a monoclonal band, shown by immunofixation to be immunoglobulin (Ig) G [kappa]. Quantification of serum immunoglobulin levels showed a high IgG level of 35.2 g/L (reference range 5.88-15.73 g/L) with normal levels of IgA (reference range, 0.46-2.87 g/L) and IgM (reference range, 0.57-2.37 g/L). Bone marrow aspiration and biopsy revealed numerous noncaseating granulomas, active hematopoiesis, and 4% plasma cells (slides not available for review). The diagnoses of sarcoidosis and monoclonal gammopathy of undetermined significance (MGUS) were established. The patient also complained of recurrent urinary tract and upper respiratory tract infections. She was treated with prednisone and showed clinical improvement. Nine months later, persistent lymphadenopathy prompted biopsy of a right supra-clavicular lymph node that revealed complete replacement of normal architecture by noncaseating granulomas. Acid-fast and methenamine silver stains were negative for organisms, and the diagnosis of sarcoidosis involving lymph node was established.
At the time of the current hospitalization, a complete blood cell count revealed a white blood cell count of 1.8 x [10.sup.9]/L; hemoglobin, 93 g/L; hematocrit, 0.30; and platelet count, 192 x [10.sup.9]/ L. Total serum protein was 87 g/L and albumin was 38 g/L (reference range, 39.7-53.4 g/L). Serum and urine protein electrophoresis demonstrated a prominent monoclonal band in the gamma region, confirmed by immunofixation to be IgG [kappa]. Serum immunoglobulin quantification showed an increased IgG level of 46.67 g/L and a decreased IgM level of 0.34 g/L. The serum IgA was normal. Magnetic resonance imaging of the spine revealed moderate narrowing of the intervertebral disk space at L5-S1 with arthritic changes and cervical stenosis. Bone marrow aspiration and biopsy were performed, which revealed multiple myeloma and numerous noncaseating granulomas consistent with sarcoidosis. The patient was treated with melphalan and prednisone and responded clinically after 2 cycles of chemotherapy.
In July 1999, follow-up bone survey showed multiple lyric bone lesions involving the thoracic and lumbar spine and a sclerotic lesion overlying the sacroiliac joint. At last follow-up, the patient was in stable condition 30 months after the diagnosis of multiple myeloma.
Bone marrow aspirate smears obtained in 1998 were aparticulate. Hematoxylin-eosin-stained sections of the core biopsy specimen showed markedly hypocellular bone marrow with severely decreased hematopoiesis. Approximately 50% of the medullary space Was involved by well-formed epithelioid granulomas without necrosis (Figure 1). Acid-fast and methenamine silver stains were negative for acid-fast bacilli and fungi, respectively. In addition, an interstitial infiltrate of atypical plasma cells was present, representing approximately 40% to 50% of the cellularity. These plasma cells were large and many were multinucleated. Small nucleoli were visible in a subset of plasma cells (Figure 2). These findings were interpreted as involvement by sarcoidosis and multiple myeloma. The percentage of plasma cells, the interstitial pattern, and the well-differentiated cytologic features are compatible with a relatively good prognosis, as described by others. (11)
[FIGURES 1 & 2 OMITTED]
Immunohistochemical studies were performed using fixed, paraffin-embedded tissue sections of the bone marrow biopsy specimen, a standard avidin-biotin peroxidase complex technique, and monoclonal antibodies specific for Ig [kappa] and [lambda] light chains (Dako Corporation, Carpinteria, Calif). The neoplastic plasma cells expressed cytoplasmic monotypic Ig [kappa] light chain (Figure 3).
[FIGURE 3 OMITTED]
The occurrence of sarcoidosis and multiple myeloma in the same patient is rare. In our review of the literature, we identified 10 patients with sarcoidosis who also developed multiple myeloma. (5-10) One case of sarcoidosis followed by extramedullary plasmacytoma also has been reported. (2) Data from these 11 cases and the current case are summarized in the Table. In 10 (83.3%) of the patients with sarcoidosis and multiple myeloma (including the case of plasmacytoma), the diagnosis of sarcoidosis preceded the diagnosis of multiple myeloma. The median interval from the time of diagnosis of sarcoidosis to the time of diagnosis of multiple myeloma was 6 years, with a range of 2 to 27 years. In 2 patients, both disorders developed simultaneously. Three cases, including the patient we describe, had both MGUS and multiple myeloma. In the case reported in this article, MGUS was diagnosed simultaneously with sarcoidosis. In the other 2 cases, sarcoidosis preceded the diagnosis of MGUS by 3 years and 6 years.
Slides of the 1994 bone marrow aspiration and biopsy specimen for our case were not available for review, and thus we cannot completely exclude the possibility that this patient had clinically indolent, so-called smoldering multiple myeloma at the time of the initial diagnosis of sarcoidosis. In fact, the serum IgG level reported in 1994, 35.2 g/L, is relatively high for MGUS and is more in keeping with immunoglobulin levels observed in patients with smoldering myeloma, that is, greater than 30 g/L. The reported plasma cell count of 4%, however, is lower than the 10% cutoff required for the diagnosis of smoldering myeloma.
In the 11 patients with sarcoidosis and multiple myeloma, including the case we report, the median age at time of diagnosis of sarcoidosis was 56 years. This age is significantly older than that of the general patient population with this disease. Sarcoidosis developing in older age groups is generally associated with a chronic active clinical course. (1) In the case we report, the clinical course of sarcoidosis was severe and disabling, and required continuous treatment consistent with chronic active sarcoidosis. Information regarding the clinical course of sarcoidosis in most of the previously reported cases associated with multiple myeloma is not available. Patients with other lymphoproliferative disorders associated with sarcoidosis, such as Hodgkin disease and non-Hodgkin lymphoma, also have been older, and sarcoidosis was most often of the chronic active type. (4,5)
As so few cases of sarcoidosis associated with multiple myeloma have been reported in the literature, no epidemiologic data are available to support the hypothesis that the risk of multiple myeloma is increased in sarcoidosis patients. However, available data do support the hypothesis that patients with sarcoidosis have an increased risk of lymphoproliferative disorders. In one epidemiologic study of 2544 sarcoidosis patients, Brincker and Wilbek (3) reported that the risk of lymphoproliferative disorders in this patient population was 11.5 times higher than expected. In a subsequent letter in 1995, Brincker (4) summarized the literature. At that time, 145 patients with sarcoidosis had developed a malignant neoplasm, including 66 cases of various types of lymphoproliferative disorders. The observed to expected ratio of lymphoid malignancies in sarcoidosis patients was 13.2. Hodgkin disease is most common, but a wide variety of B-cell non-Hodgkin lymphomas and leukemias and rare T-cell neoplasms also have been reported. (2-4)
The explanation for the relationship between sarcoidosis and lymphoproliferative disorders, and potentially multiple myeloma, is unknown. There is abundant evidence that patients with sarcoidosis have immune system dysregulation, including activation of CD4-positive T-helper/inducer cells, increased secretion of various cytokines, and decreased CD8-positive T-suppressor/cytotoxic cells. (1,2) B-cell function is relatively unaffected in sarcoidosis, but with defective T-cell suppression and increased cytokine secretion, B cells are likely to be stimulated continuously. In one relevant study, Hunninghake and Crystal (12) showed that untreated patients with pulmonary sarcoidosis have greater numbers of IgG- and IgM-secreting cells per [10.sup.3] lung lymphocytes, as compared with those of normal individuals. These investigators also showed that B lymphocytes of normal individuals, when cocultured with purified T lymphocytes from the lungs of patients with sarcoidosis, were induced to differentiate into immunoglobulin-secreting cells. (12) Polyclonal hypergammaglobulinemia, often seen in sarcoidosis patients, may be explained by this mechanism. The extended half-life of B lymphocytes and plasma cells in sarcoidosis patients may increase their risk of undergoing genetic events that result in neoplastic transformation.
The 2-hit hypothesis of carcinogenesis, as it applies to multiple myeloma, postulates that a first oncogenic event results in MGUS and that a second event is necessary for the development of multiple myeloma. (13) Up to 16% of patients with MGUS develop multiple myeloma with long-term follow-up (30 years or more). The annual actuarial risk of developing multiple myeloma subsequent to MGUS is 0.8% in an unselected patient population. (13) In this study, the median interval between MGUS and multiple myeloma in the 3 cases of MGUS associated with sarcoidosis is 4 years. This finding may suggest that MGUS in sarcoidosis patients more rapidly progresses to multiple myeloma than does MGUS in other patients, although the small number of patients precludes any definite conclusions. It is also likely that patients with sarcoidosis in association with MGUS who do not develop multiple myeloma are underreported in the literature.
In summary, we describe a patient with sarcoidosis and MGUS who developed multiple myeloma 4 years later to call attention to this rare occurrence. Eleven other cases have been reported to date, mostly in the clinical literature. The explanation for this association is unknown. Although a coincidental relationship cannot be excluded, the number of cases and the temporal relationship between sarcoidosis and multiple myeloma suggest a true association. Immune dysregulation, currently considered to explain the increased risk of lymphoproliferative disorders in patients with sarcoidosis, also may be involved in the pathogenesis of multiple myeloma in this patient group.
Summary of Cases of Sarcoidosis and Multiple Myeloma Reported in the Literature * Age, y/ Monoclonal History Source, y Sex Interval, y Protein of MGUS Schafer & Miller, (6) 1979 64/F 5 IgA - Petersson et al, (7) 1987 42/M 6 IgG [lambda] - 58/M 6 IgA [kappa] - 56/M 3 IgG [kappa] - 65/F 12 IgG [lambda] - 60/F None IgG [lambda] U Santos et al, (8) 1997 49/F None IgG U Selroos et al, (9) 1974 49/F 6 IgG + Brincker, (5) 1986 63/M 22 IgG [kappa] - Karakantza et al, (2) 61/M 27 Ig [kappa] - 1996 ([dagger]) Uchiumi et al (10) 1993 56/F 2 IgA [kappa] + Present case 49/F 4 IgG [kappa] + * Age refers to age at time of diagnosis of multiple myeloma; Interval, the interval between the time of diagnosis of sarcoidosis and the time of diagnosis of multiple myeloma. MGUS indicates monoclonal gammopathy of undetermined significance; U; unknown. ([dagger]) This case was an extramedullary plasmacytoma without bone marrow involvement.
(1.) Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology and therapeutics. Adv Intern Med. 2000;45:209-257.
(2.) Karakantza M, Matutes E, MacLennan K, O'Connor NTJ, Srivastava PC, Catovsky D. Association between sarcoidosis and lymphoma revisited. J Clin Pathol. 1996;49:208-212.
(3.) Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer. 1974;29:247-251.
(4.) Brincker H. Sarcoidosis and malignancy. Chest. 1995; 108:1472-1474.
(5.) Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer. 1986;54: 467-473.
(6.) Schafer A, Miller JB. Association of IgA multiple myeloma with pre-existing disease. Br J Haematol 1979;41:19-24.
(7.) Pettersson T, Koivunen E, Ilvonen M, et al. Sarcoidosis and multiple myeloma: an association. Br Med J. 1987;295:958.
(8.) Santos CP, Roca JR, Manero NG, et al. Mieloma multiple y sarcoidosis de presentacion simultanea. Sangre. 1997;42:411-413.
(9.) Selroos O, Brander L, Virolainen M. Sarcoidosis and myeloma of lambda-type IgG. Acta Med Scand. 1974;1-2:59-63.
(10.) Uchiumi H, Murakami H, Matsushima T, et al. Does sarcoidosis induce multiple myeloma? Am J Hematol. 1993;44:220.
(11.) Sailer M, Vykoupil K-F, Peest D, et al. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol 1995;54:137-146.
(12.) Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. J Clin Invest. 1981;67:86-92.
(13.) Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336: 1657-1664.
Accepted for publication August 8, 2001.
From the Division of Pathology and laboratory Medicine, The University of Texas M. O. Anderson Cancer Center, Houston, Tex (Ors Sen and Medeiros); and the Department of Pathology and Laboratory Medicine, Emory University Medical Center, Atlanta, Ga (Dr Mann).
Reprints: L. Jeffrey Medeiros, MD, Division of Pathology and Laboratory Medicine, Box 72, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Bird, Houston, TX 77030 (e-mail: email@example.com).
|Printer friendly Cite/link Email Feedback|
|Author:||Sen, Filiz; Mann, Karen P.; Medeiros, L. Jeffrey|
|Publication:||Archives of Pathology & Laboratory Medicine|
|Article Type:||Statistical Data Included|
|Date:||Mar 1, 2002|
|Previous Article:||Mesenteric paraganglioma: a case report and review of the literature. (Case Reports).|
|Next Article:||Malignant intrahepatic biliary papillomatosis associated with viral C cirrhosis. (Case Reports).|